Skip to content

HANSOH PHARMAC. HD-00001 Price, Chart & Factor Analysis

Free Data & Analytics Access

Next earnings: Thu, Apr 1, 2027, after the market closes · estimates and history

HANSOH PHARMAC. HD-00001 · E.3KY.F · Germany
Use symbol E.3KY.F in our API & Excel add-in to retrieve this data ↓
3.52
(-0.04%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum -100%
Trend -75%
Bubble Risk LOW
Realised Volatility (20D) 39.99%

HANSOH PHARMAC. HD-00001 Forecast

HANSOH PHARMAC. HD-00001 short-term momentum is strongly negative (up over 0 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term SELL signal. The long-term trend is strongly negative (1 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term SELL signal. Based on 20-day realised volatility of 40.0% a year, a typical one-standard-deviation range is 3.3255–3.7225 over a week, 3.1172–3.9308 over a month and 2.1147–4.9333 over a year. (Signals as of 22 Nov 2026.)

HANSOH PHARMAC. HD-00001 Price Chart

MacroFinance.ai

HANSOH PHARMAC. HD-00001 Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
HANSOH PHARMAC. HD-00001
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
HANSOH PHARMAC. HD-00001
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
HANSOH PHARMAC. HD-00001
Signal
0
ⓘLatest reading of Signal.
Teal = supportive for HANSOH PHARMAC. HD-00001, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

HANSOH PHARMAC. HD-00001 fundamentals: income statement, balance sheet & cash flow

HANSOH PHARMAC. HD-00001 reported revenue of €15.03bn and net income of €5.56bn in FY2025, the year ended 31 December 2025 — revenue up 22.6% and net income up 27.1% on the prior year. Free cash flow was €6.25bn. These figures are as reported in the filings, not restated: 5 fiscal years of history, back to December 2021.

Revenue (FY2025)
€15.03bn
+22.6%
Net income
€5.56bn
+27.1%
Gross margin
90.03%
Free cash flow
€6.25bn
+87.2%
HANSOH PHARMAC. HD-00001 income statement, annual, as reported · EUR billions unless stated
EUR billionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue15.0312.2610.109.389.94
Cost of revenue1.501.111.030.870.87
Gross profit13.5311.169.078.529.07
Research & development3.362.702.101.691.80
Operating income5.554.032.842.793.03
EBITDA6.955.494.203.35—
Interest expense0.000.010.070.060.05
Pre-tax income6.555.093.772.953.30
Net income5.564.373.282.582.71

Download HANSOH PHARMAC. HD-00001 fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.3KY.F&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks the full history, the filing vintages behind each number and API access.
Create free account

Figures in EUR, statements as filed. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic.

Research on HANSOH PHARMAC. HD-00001

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

HANSOH PHARMAC. HD-00001 Trading Strategies

9 backtested tactical asset allocation strategies hold VGK (European market), the closest tradable exposure to HANSOH PHARMAC. HD-00001; 1 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

Explore all strategies →

Statistical Distribution of Returns

Plus

How HANSOH PHARMAC. HD-00001’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how HANSOH PHARMAC. HD-00001 behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About HANSOH PHARMAC. HD-00001 (Germany)

HANSOH PHARMAC. HD-00001 is a listed security in Germany. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

Frequently asked questions

What is HANSOH PHARMAC. HD-00001?
HANSOH PHARMAC. HD-00001 is a listed security in Germany. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest HANSOH PHARMAC. HD-00001 price?
The latest close is 3.524 (22 Nov 2026), -0.04% on the day. The price at the top of the page refreshes during the trading day.
Is HANSOH PHARMAC. HD-00001 in an uptrend?
As of 22 Nov 2026, short-term momentum is strongly negative (0 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly negative (1 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is HANSOH PHARMAC. HD-00001?
20-day realised volatility is 40.0% a year (22 Nov 2026), which implies a typical one-standard-deviation move of about 11.5% over a month and 5.6% over a week.
What factors affect HANSOH PHARMAC. HD-00001?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to HANSOH PHARMAC. HD-00001, grouped as Quantitative Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade HANSOH PHARMAC. HD-00001?
9 backtested tactical asset allocation strategies trade HANSOH PHARMAC. HD-00001 through VGK; 1 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are HANSOH PHARMAC. HD-00001 returns analysed?
The Statistical Distribution of Returns section shows the distribution of HANSOH PHARMAC. HD-00001 daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free HANSOH PHARMAC. HD-00001 historical data?
In the Free historical data section of this page: the last 10 years of HANSOH PHARMAC. HD-00001 daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free HANSOH PHARMAC. HD-00001 historical data (last 10 years)

Browse or instantly download the last 10 years of HANSOH PHARMAC. HD-00001 daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.3KY.F&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-203.524
2026-11-193.69
2026-11-183.739
2026-11-173.811
2026-11-163.849
2026-11-133.92
2026-11-123.942
2026-11-113.909
2026-11-103.913
2026-11-093.877
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, as well as a strategic collaboration with F. Hoffmann-La Roche Ltd for developing antibody-drug conjugate programs. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited operates as a subsidiary of Stellar Infinity Company Ltd.